CTXR: LYMPHIR launch drives early revenue and creates an investment arbitrage opportunity
Citius Pharmaceuticals and Citius Oncology have launched LYMPHIR for CTCL, achieving early revenue and broad payer coverage. The company reports strong clinical results, a robust pipeline, and highlights an investment opportunity due to a market cap disconnect between the two entities.Based on Citi…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.